The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics
Pharmacopsychiatry · 2024-03 · 57 (02) · 69-77
DOI: 10.1055/a-2248-6924 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacopsychiatry, online erschienen am 14.02.2024. Verfasst von Maike Scherf-Clavel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, 97080 Würzburg, Germany. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Amitriptyline. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
CYP2D6 and CYP2C19 functional status as defined by genotype is modulated by phenoconversion (PC) due to pharmacokinetic interactions. As of today, there is no data on the effect size of PC for CYP2C19 functional status. The primary aim of this study was to investigate the impact of PC on CYP2C19 functional status.
Methods
Two patient cohorts (total n=316; 44.2±15.4 years) were investigated for the functional enzyme status of CYP2C19 applying two different correction methods (PCBousman, PCHahn&Roll) as well as serum concentration and metabolite-to-parent ratio of venlafaxine, amitriptyline, mirtazapine, sertraline, escitalopram, risperidone, and quetiapine.
Results
There was a decrease in the number of normal metabolizers of CYP2C19 and an increase in the number of poor metabolizers. When controlled for age, sex, and, in the case of amitriptyline, venlafaxine, and risperidone, CYP2D6 functional enzyme status, an association was observed between the CYP2C19 phenotype/functional enzyme status and serum concentration of amitriptyline, sertraline, and escitalopram.
Discussion
PC of CYP2C19 changes phenotypes but does not improve correlations with serum concentrations. However, only a limited number of patients received perturbators of CYP2C19. Studies with large numbers of patients are still lacking, and thus, it cannot be decided if there are minor differences and which method of correction to use. For the time being, PC is relevant in individual patients treated with CYP2C19-affecting drugs, for example, esomeprazole. To ensure adequate serum concentrations in these patients, this study suggests the use of therapeutic drug monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, 97080 Würzburg, Germany.
- Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Frankfurt, 60528 Frankfurt, Germany.
- Department of Mental Health, Varisano Hospital Frankfurt Hoechst, 65929 Frankfurt, Germany.
Zitieren
APA
Scherf-Clavel, M., Weber, H., Unterecker, S., Frantz, A., Eckert, A., Reif, A., Deckert, J., & Hahn, M. (2024). The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics. Pharmacopsychiatry, 57(02), 69-77. https://doi.org/10.1055/a-2248-6924
Vancouver
Scherf-Clavel M, Weber H, Unterecker S, Frantz A, Eckert A, Reif A, et al. The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics. Pharmacopsychiatry. 2024;57(02):69-77. doi:10.1055/a-2248-6924
BibTeX
@article{ScherfClavel2024,
author = {Scherf-Clavel, Maike and Weber, Heike and Unterecker, Stefan and Frantz, Amelie and Eckert, Andreas and Reif, Andreas and Deckert, Jürgen and Hahn, Martina},
title = {The Relevance of Integrating CYP2C19 Phenoconversion Effects into Clinical Pharmacogenetics},
journal = {Pharmacopsychiatry},
year = {2024},
volume = {57},
number = {02},
pages = {69--77},
doi = {10.1055/a-2248-6924}
}
EUVIMED